NervGen Pharma Corp. (NasdaqCM: NGEN)
Health Care · Pharmaceuticals · CA
$2.00
+7.53% today · -24.2% 1Y
NervGen Pharma Corp. (NasdaqCM: NGEN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $215.05M and employs 8 people.
Over the last twelve months the share price has lost 24.2%, trading between 1.58 and 6.30.
Tweenvest scores NervGen Pharma Corp. across four factors: quality 24/100. Its strongest factor is quality.
NGEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $215.05M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.91
- Dividend yield
- —
- Beta (5Y)
- 0.69
- 52-week high
- $6.30
- 52-week low
- $1.58
- Avg volume (3M)
- —
- Shares outstanding
- 107.52M
- Employees
- 8
- Next earnings
- —
About NervGen Pharma Corp.
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
- ISIN
- CA64082X2032
- Founded
- 2017
- Listed since
- Feb 8, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,243.44 | -0.28% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $270.51 | -0.93% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.36 | -0.20% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.30 | +0.24% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £122.24 | +0.94% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.92 | -0.18% |
Figures last refreshed Aug 18, 2026.